Clinical Outcomes of Interposition Graft Versus Superior Capsular Reconstruction in Patients With Irreparable Rotator Cuff Tears

A Systematic Review and Meta-analysis

Samuel Baek,* MD, Myung Ho Shin,† MD, Tae Min Kim,† MD, Je Min Im,† MD, Kyung-Soo Oh,† MD, PhD, and Seok Won Chung,†‡ MD, PhD

Investigation performed at the Department of Orthopaedic Surgery, Konkuk University School of Medicine, Seoul, Republic of Korea

Background: Interposition grafting (IG), also called bridging grafting, and superior capsular reconstruction (SCR) are the most commonly used joint-preserving surgical methods for irreparable rotator cuff tears (RCTs).

Purpose: To compare the effectiveness of IG versus SCR to treat patients with irreparable RCTs.

Study Design: Systematic review; Level of evidence, 4.

Methods: A literature search was performed in MEDLINE, Embase, and Scopus. Included in this review were clinical studies evaluating the effect of IG or SCR in patients with irreparable RCTs with a minimum follow-up of 1 year. Various clinical results from the studies were extracted and compared between IG and SCR, and among them, the results of the American Shoulder and Elbow Surgeons score, graft retear rate, and complication rate were included in the meta-analysis.

Results: Of 1638 identified articles, 17 (10 studies of IG involving 321 patients and 7 studies of SCR involving 357 patients) were selected. Both surgical methods showed significantly improved clinical outcomes in all but 1 study; however, the IG group had lower pain visual analog scale score, higher Constant score, and bigger active forward flexion and internal rotation compared with the SCR group (all \( P < .001 \)). The meta-analysis showed no difference in the American Shoulder and Elbow Surgeons score between groups (\( P = .44 \)), but showed a significantly lower complication rate in the IG group compared with the SCR group (1.12% vs 8.37%, respectively; \( P < .001 \)). The graft retear rate was not significantly different between groups (IG = 10.64% vs SCR = 12.67%; \( P = .79 \)). The meta-analysis of graft type indicated no difference between groups in retear rate (autograft: 95% CI, 0.045-0.601; \( I^2 = 93.28 \) [IG], 91.27 [SCR]; \( P = .22 \); allograft: 95% CI, 0.041-0.216; \( I^2 = 80.39 \) [IG], 69.12 [SCR]; \( P = .64 \)) or complication rate (autograft: 95% CI, 0.009-0.150; \( I^2 = 0 \) [IG], 65.89 [SCR]; \( P = .25 \); allograft: 95% CI, 0.012-0.081; \( I^2 = 0 \) [IG], 30.62 [SCR]; \( P = .09 \)).

Conclusion: Both IG and SCR techniques resulted in improvement in patients with irreparable RCTs. Meta-analysis showed a lower complication rate in the IG group; however, the lack of randomized studies limited our conclusions.

Keywords: irreparable rotator cuff tear; interposition graft; bridging graft; superior capsular reconstruction; clinical outcome

Rotator cuff tear (RCT) is one of the most commonly diagnosed diseases in orthopaedics. Recently, the techniques and instrumentation used for surgical repair of torn rotator cuffs have rapidly improved, and the clinical and functional outcomes of rotator cuff repair have been satisfactory. Nevertheless, large to massive RCTs are still a formidable and challenging problem, and in some large to massive RCTs, the direct repair of the native rotator cuff tendons to the footprint of the greater tuberosity is impossible, even after adequate release, because of retraction, attenuation, and inelasticity of tendons.4

Many surgical procedures have been introduced for the treatment of irreparable RCTs: arthroscopic debridement,27 tuberoplasty,16,54 partial repair,3 interposition grafting (IG),41,46 superior capsular reconstruction (SCR),34 tendon transfers,15,17 reverse total shoulder arthroplasty,6,39,50 and arthrodesis.11 Among these surgical procedures, IG and SCR are 2 of the most commonly performed. During IG, a patch graft is used to bridge the gap between the torn tendon and the footprint, for a
tension-free repair; in SCR, joint function and stability are restored by reconstructing the superior capsule. In both methods, the lateral margin of the graft is attached on the footprint of the greater tuberosity, but the difference is that the medial end of the graft is attached to the torn tendon end in IG and to the superior glenoid in SCR. Studies have shown that both these methods lead to satisfactory results, with good pain relief and improved function. However, to our knowledge, there have been no original articles that directly compared the clinical outcomes of IG and SCR. Most studies have evaluated the technique and outcomes of IG or SCR separately, without a control group or a randomized design. There have been only 2 systematic reviews comparing IG and SCR, and they lacked meta-analyses of the clinical outcomes, graft retear rates, and complication rates. The purpose of this study was to comprehensively compare the clinical outcomes of the IG and SCR procedures for irreparable RCTs and include a meta-analysis. We hypothesized that IG, which preserves active rotator cuff muscle function and strength, would show better clinical outcomes and lower graft retear and complication rates compared with SCR.

METHODS

Identification and Selection of the Literature

This systematic review and meta-analysis followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. A systematic search of the literature in the MEDLINE, Embase, and Scopus databases using controlled vocabulary and keywords was conducted by 2 authors (S.B. and M.H.S.) on March 14, 2020. In addition, the reference lists of retrieved studies and previous literature reviews were manually screened. The detailed search terms were as follows: (1) irreparable rotator cuff AND (tear OR injury OR repair) AND (superior capsule OR superior cuff OR superior capsule); (2) irreparable rotator cuff AND (tear OR injury OR repair) AND (interposition OR bridging); (3) irreparable rotator cuff AND (tear OR injury OR repair) AND (superior capsular OR superior capsule). There was a time limitation between 2000 and 2020 for the publication date.

Eligibility Criteria

The inclusion criteria were as follows: (1) irreparable RCT, which is the inability to suture the rotator cuff back to the footprint at \( \leq 60^\circ \) of abduction without undue tension despite adequate release, (2) clearly defined procedures of IG or SCR used, (3) clinical outcomes measured at least 1 year postoperatively, (4) postoperative radiographic outcomes at a minimum of 1 year after surgery, (5) published in English-language, peer-reviewed journals, and (6) full text of studies available. The exclusion criteria were as follows: (1) nonclinical studies (eg, animal, biomechanical, basic science, and cadaveric studies), (2) expert opinions or review articles, (3) level 5 studies as designated according to the Oxford Centre for Evidence-Based Medicine, and (4) studies with duplicated characteristics data.

Study Selection

Two authors (S.B. and M.H.S.) independently assessed all retrieved studies by title and abstract. Articles that initially met the inclusion and exclusion criteria were then further evaluated by a full-text review. If there was disagreement with regard to the initial review, studies were reviewed by the senior author (S.W.C.) to make an ultimate decision.

Data Collection Process

Two authors (S.B. and M.H.S.) independently extracted all relevant data from eligible studies. Discrepancies were resolved by consensus or by a third author (S.W.C.) if consensus could not be reached. Extracted information was as follows: general study information (author, year of publication, study design, and level of evidence), patient characteristics (sample size, mean age, sex, hand dominance, and mean follow-up duration), preoperative functional scores (pain visual analog scale [VAS], American Shoulder and Elbow Surgeons [ASES] score, Constant score, and active range of motion [ROM]) and radiologic fatty infiltration data of each rotator cuff muscle, surgical intervention information (surgical position, surgical procedures performed [open or arthroscopic], graft type), imaging method (ultrasound [US] or magnetic resonance imaging [MRI]), and outcomes (graft retear rate, complication rate, pain VAS, ASES score, Constant score, active ROM, and abduction strength). Partial tear of the graft (also described as a partially intact graft or partial healing of the graft) was not regarded as a graft retear; only a complete graft retear or failure was defined as a graft retear in this review.

Data Analysis

A systematic review and qualitative analysis were performed for all eligible studies. Patient characteristics and clinical outcomes were documented in the form of means and standard deviations. The outcomes of interest for this study were graft retear rate, complication rate, pain VAS, ASES, Constant score, active ROM, and abduction strength; and among these, the meta-analysis between IG

---

1Address correspondence to Seok Won Chung, MD, PhD, Department of Orthopaedic Surgery, Center for Shoulder and Elbow Surgery, Konkuk University School of Medicine, 120 -1 Neungdong-ro (Hwayang-dong), Gwangjin-gu, Seoul 143-729, Republic of Korea (email: smilecsw@gmail.com).
2Department of Orthopaedic Surgery, Seoul Red Cross Hospital, Seoul, Republic of Korea.
3Department of Orthopaedic Surgery, Konkuk University School of Medicine, Seoul, Republic of Korea.
4Final revision submitted February 1, 2021; accepted February 24, 2021.
5One or more of the authors declared the following potential conflicts of interest or source of funding: This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (NRF-2020R1A2B5B01001936). AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto.
and SCR was performed for the ASES score, graft retear rate, and complication rate, as those were common denominators reported by most of the studies. Furthermore, outcomes according to graft type (autograft vs allograft) were compared.

Quality Assessment

All studies that met inclusion criteria were assessed for methodologic quality by 2 independent reviewers (S.B. and M.H.S.) using the methodological index for non-randomized studies (MINORS). The 12-item MINORS questionnaire is scored as 0 (not reported), 1 (reported but inadequate), and 2 (adequate), with a maximum score of 16 for noncomparative studies and 24 for comparative studies. Noncomparative studies with a MINORS score of ≥13 and comparative studies ≥21 are considered to have a low risk of bias. The methodologic quality was stratified according to the MINORS score for noncomparative studies and was reported as very low (0-5), low (6-10), fair (11-15), and good (16). For any calculated score, discrepancies between reviewers were resolved by consensus.

Statistical Analysis

All statistical analyses were performed using Comprehensive Meta-Analysis Version 3 (Biostat). The study characteristics at baseline and the clinical outcomes at preoperative status and final follow-up were summarized in the form of means and standard deviations using the Hozo et al formula calculated from the median, range, and size of sample. The overall prevalence was computed for both groups by the use of the Wilson procedure with correction for continuity. Heterogeneity between studies was quantified using I² values. Ranges across outcome measures were reported by most of the studies. Furthermore, outcomes according to follow-up period than in the SCR group (35.92 ± 7.71 months, respectively; P < .001). Fatty infiltration grade, as defined by Goutallier et al, was documented in 6 of the 17 studies (82.35%), and Constant scores in 8 of the 17 studies (47.05%), and ASES scores in 14 of the 17 studies (82.35%), and Constant scores in 8 of the 17 studies (47.05%).

Risk-of-Bias Assessment

There were 5 studies with evidence level 4 and 12 studies with evidence level 4. Nine of 14 noncomparative studies had a low risk of bias. However, none of the comparative studies had a low risk of bias. The results of the assessment of methodologic quality using MINORS scores are summarized in Appendix Table A2.

Clinical Outcomes

Functional Outcome Scores. Functional outcome scores were reported in all 17 studies, but 2 studies only reported postoperative scores. The most commonly documented outcome scores were pain VAS, ASES, and Constant scores. Pain VAS scores were reported in 10 of the 17 studies (58.82%), ASES scores in 14 of the 17 studies (82.35%), and Constant scores in 8 of the 17 (47.05%).

5References 22, 4, 5, 9, 13, 20, 21, 28, 29, 31, 37, 38, 40, 43, 44, 47, 58.
The University of California Los Angeles shoulder score,37,58 12-Item Short Form Health Survey score,20,21 and Oxford Shoulder Score42 were reported in the IG group, and the Japanese Orthopedic Association score31 and Subjective Shoulder Value score9,13 were reported in the SCR group. However, these scores existed only in 1 group (either IG or SCR group) and thus were excluded from the comparison.

Range of Motion. ROM was reported in 13 of the 17 studies (76.47%), and active forward flexion (FF), external rotation (ER), internal rotation (IR), and abduction were documented. Active IR was measured in various ways. One study4 used the Constant score’s IR points, another 1 study40 measured the IR with an arm at 90° abduction position, and the other studies13,28,31,37,38,47 measured the IR by determining how far the patient’s thumb could reach along the spinal segments (segments from T1 to T12 as 1-12, segments from L1 to L5 as 13-17, and the sacrum as 18). This last definition of IR was used for the comparison between groups. Abduction was reported in 5 of the 17 studies (29.41%), but only 1 study44 in the SCR group; thus, a mean comparison between groups was not possible.

Strength Testing. Nine of the 17 studies (52.94%) measured strength in various directions using methods such as the Constant score strength subscale (points),4 digital dynamometer (lb, N),20,44,47 Nottingham mecmesin myometer (kg),5,29 or modified Medical Research Council scale (grade)20, medical Research Council scale (grade)20,21, thus, a direct comparison of the strength results was restricted. In most of the studies (7 of 9 studies),4,5,20,21,40,44,47 strength significantly improved postoperatively, but 1 study37 in the IG group (using autograft) reported no difference in IR strength at final follow-up, and another 1 study29 in the SCR group (using autograft) reported no substantial postoperative change in supraspinatus and external rotator muscle strength.

Graft Repair Integrity. All studies (720 shoulders; 357 in the IG group and 363 in the SCR group) reported complete graft retear rates among their cohorts at final follow-up, which ranged from 12 to 50.3 months. Graft repair integrity was evaluated by using MRI in 8 studies,9,13,29,31,37,38,44,58 US in 6 studies,4,20,21,40,44,47 and a combination of both in 3 studies.22,45

Complications. Complications were reported in most of the studies (15 of the 17 studies), but 2 studies28,44 did not
document any complications. In the IG group, 4 patients with complications (3 superficial subcutaneous infections and 1 deep wound infection) were reported, and all were resolved after arthroscopic irrigation and debridement and antibiotic treatment. In the SCR group, 20 patients with complications (3 deep infection, 4 suture anchor pull-out, 2 severe shoulder contracture, 1 discomfort in the gluteal muscle after fascia lata autograft surgery, 1 persistent biceps pain, and 9 nonspecified) occurred, and 8 cases (40%) required revision surgery (debridement and antibiotic spacer, arthroscopic capsular release, open subpectoral tenodesis, reverse total shoulder arthroplasty, or revision SCR). There were no cases of definitive graft rejection in either group.

For all studies, mean pre- and postoperative clinical scores, ROM, graft retear rate, and complication rate are described in Appendix Tables A3 and A4.

The IG group showed significantly lower pain VAS, higher ASES score, and better active FF, ER at side, and IR at final follow-up (all \( P < .001 \)). On comparing the mean

### TABLE 1
Summary of the Characteristics and Demographics of the Included Studies**

| Lead Author (Year) | Study Type (LOE) | Patients/Shoulders, n | Sex, M: F, n | Mean age, y | Mean Follow-up, mo | Surgery method | Position | Graft Type |
|--------------------|------------------|-----------------------|--------------|-------------|-------------------|---------------|----------|-----------|
| **Interposition Grafting** |
| Audenaert (2006)* | Cohort (3)       | 41/41                 | NR           | 67          | 43                | Open          | NR       | Synthetic graft (Mersilene mesh) |
| Badhe (2008)**    | Case series (4)  | 10/10                 | 5.5          | 66          | 54                | Open          | Beach-chair | Xenograft (Zimmer patch, porcine dermal collagen patch) |
| Wong (2010)**     | Case series (4)  | 45/80                 | 36.9         | 53.6        | 24                | Arthroscopy   | Lateral | Allograft (GraftJacket) |
| Gupta (2012)**    | Case series (4)  | 24/24                 | NR           | 63          | 36                | Arthroscopy   | Beach-chair | Allograft (GraftJacket) |
| Gupta (2013)**    | Case series (4)  | 26/27                 | NR           | 60          | 32                | Arthroscopy   | Beach-chair | Xenograft (porcine dermal ECM; Conexa) |
| Mori (2013)**     | Cohort (3)       | 24/24                 | 17.7         | 65.9        | 35.5              | Arthroscopy   | Beach-chair | Autograft (FL) |
| Mori (2015)**     | Cohort (3)       | 19/19                 | 11.8         | 67          | 29                | Arthroscopy   | Beach-chair | Synthetic graft (PTFE patch) |
| Neumann (2017)**  | Case series (4)  | 61/61                 | NR           | 50.3        | 50.3              | Arthroscopy   | Beach-chair | Xenograft (porcine dermal ECM; Conexa) |
| Pandey (2017)**   | Cohort (3)       | 13/13                 | NR           | 57          | 24                | Open          | Beach-chair | Allograft (GraftJacket) |
| Seker (2018)**    | Case series (4)  | 58/58                 | 37:21        | 67          | 36                | Open (10)/arthroscopy | Beach-chair | Synthetic graft (PTFE patch) |
| **Superior Capsular Reconstruction** |
| Hirahara (2017)** | Case series (4)  | 8/8                   | 6.2          | 61.3        | 24                | Arthroscopy   | Beach-chair | Allograft (ArthroFlex) |
| Pennington (2018)** | Case series (4) | 86/88                | 59.27        | 59.4       | 12                | Arthroscopy   | Lateral | Allograft (3.0 mm—thick acellular dermal allograft) |
| Mihata (2018)**   | Cohort (3)       | 100/100               | NR           | 66.9        | 24                | Arthroscopy   | Lateral | Autograft (FL) |
| Lee (2018)**      | Case series (4)  | 32/36                 | 22.10        | 60.9        | 24                | Arthroscopy   | Beach-chair | Autograft (FL) |
| Denard (2018)**   | Case series (4)  | 59/59                 | 39.20        | 62          | 12                | Arthroscopy   | Lateral | Allograft (acellular dermal allograft) |
| Lim (2019)**      | Case series (4)  | 31/31                 | 9.22         | 65.3        | 12                | Arthroscopy   | Beach-chair | Autograft (FL) |
| Burkhart (2020)** | Case series (4)  | 41/41                 | 33:8         | 64          | 24                | Arthroscopy   | Lateral | Allograft (3.0 mm—thick acellular dermal allograft) |

**ECM, extracellular tissue matrix; F, female; FL, fascia lata; LOE, level of evidence; M, male; NR, not reported; PTFE, polytetrafluoroethylene.

*We attempted to use autografts in all patients; however, in sarcopenic patients, patients with a history of surgery at the thigh level, or patients who did not want an autograft, allografts were used.
differences between pre- and postoperative functional outcome scores and active ROM, we found the IG group showed significantly improved pain VAS score, Constant score, and active FF and IR (all \( P < .001 \)). Although there was no difference in the final Constant score between groups, the mean difference was significantly higher in the IG group, indicating greater improvement in Constant scores postoperatively compared with the SCR group. With respect to differences in patient-reported outcome measures between groups, only the Constant score reached the minimal clinically important difference (MCID) of 15 points as reported in previous studies. But mean improvement in the ASES score was significantly better in the SCR group. There was no significant difference in the amount of gains in ER between groups (Appendix Table A5).

For the graft retear rate, there were 38 cases of complete graft retear in the IG group (documented by site as follows: at the repaired infraspinatus \( 19 \) cases), graft-humerus interface \( 2 \) cases), graft-tendon interface \( 2 \) cases), both the graft-humerus and graft-tendon interface \( 1 \) case), and not specified \( 12 \) cases); and there were 46 cases of complete graft retear in the SCR group (documented by site as follows: at the lateral humeral attachment site \( 31 \) cases), graft-midsubstance \( 4 \) cases), medial glenoid site \( 4 \) cases), and not specified \( 7 \) cases). The total graft retear rate was slightly lower in the IG group, although it did not reach statistical significance (IG vs SCR: \( 12.2 \% \) vs \( 10.6 \% \); \( P = .397 \)); however, in the subgroup analysis of the autograft results, the IG group showed a significantly higher graft retear rate compared with the SCR group (IG vs SCR: \( 51.2 \% \) vs \( 10.7 \% \); \( P < .001 \)). The total complication rate was significantly lower in the IG group compared with the SCR group (IG vs SCR: \( 1.1 \% \) vs \( 8.4 \% \); \( P < .001 \)), and in the subgroup analysis of the autograft and allograft results, the IG group also showed significantly lower complication rates (autograft: IG vs SCR: \( 12.2 \% \), \( P = .013 \); allograft: IG vs SCR: \( 3.7 \% \), \( P = .197 \)), although the allograft subgroup analysis did not reach statistical significance (Appendix Table A6).

With regard to graft type, the xenograft and synthetic graft were used only in the IG group, and the results of the xenograft were poor. However, the results of the synthetic graft used in the IG were overall satisfactory when evaluated with a frequency-weighted mean (Appendix Table A7).

Meta-Analysis

**ASES Score.** This meta-analysis was possible in 8 studies (43 shoulders in the IG group and 327 shoulders in the SCR group) in which the ASES results were presented as mean \( \pm SD \), and all these 8 studies used arthroscopic surgeries. The mean differences from preoperative to last follow-up of the IG and SCR groups were 43.49 (95% CI, 24.29-62.70) and 36.68 (95% CI, 28.27-45.09), respectively. Although the IG group showed a higher mean ASES score than the SCR group, the meta-analysis did not show a statistical difference between groups (95% CI, 30.07-45.48; \( I^2 = 97.24 \) [IG], 97.40 [SCR]; \( P = .44 \)) (Appendix Figure A1). A subgroup analysis by autograft or allograft was not possible because of the limited number of cases.

**Graft Rетеar Rate.** All studies reported the graft retear rate (357 shoulders in the IG group and 363 shoulders in the SCR group). Although slightly lower in the IG group than the SCR group, there was no significant difference in the graft retear rate between groups in the meta-analysis (95% CI, 0.073-0.223; \( I^2 = 81.97 \) [IG], 81.44 [SCR]; \( P = .79 \)) (Appendix Figure A2).

The graft retear rate of autografts was reported in 4 studies (43 shoulders in the IG group and 131 shoulders in the SCR group), and that of allografts was reported in 7 studies (117 shoulders in the IG group and 196 shoulders in the SCR group). There were no differences in the graft retear rate according to graft type in the meta-analysis (autograft: 95% CI, 0.045-0.601; \( I^2 = 93.28 \) [IG], 91.27 [SCR]; \( P = .22 \); allograft: 95% CI, 0.041-0.216; \( I^2 = 80.39 \) [IG], 69.12 [SCR]; \( P = .64 \)) (Appendix Figures A3 and A4). The statistical difference of the frequency-weighted mean of the autografts shown in Appendix Table A6 disappeared in the meta-analysis because of the wide confidence interval.

**Complication Rate.** The complication rate was reported in all except 2 of the studies (357 shoulders in the IG group and 239 shoulders in the SCR group). There was a statistically significant difference in the total complication rate in favor of the IG group (95% CI, 0.022-0.065; \( I^2 = 0 \) [IG], 52.83 [SCR]; \( P < .001 \)) (Figure 2).

The complication rate of autografts was reported in 4 studies (43 shoulders in the IG group and 131 shoulders in the SCR group), and that of allografts was reported in 6 studies (117 shoulders in the IG group and 108 shoulders in the SCR group). There were no differences in the complication rate according to graft type in the meta-analysis (autograft: 95% CI, 0.009-0.150; \( I^2 = 0 \) [IG], 65.89 [SCR]; \( P = .25 \); allograft: 95% CI, 0.012-0.081; \( I^2 = 0 \) [IG], 30.62 [SCR]; \( P = .09 \)) (Appendix Figures A5 and A6).

**Discussion**

In this systematic review, we found that both the IG and SCR groups showed improved outcomes. The IG group displayed a tendency toward better results in overall clinical outcomes compared with the SCR group, although several outcomes did not reach to the significant level. Specifically, in the frequency-weighted mean analysis, the IG group showed better results in pain VAS, Constant score, active FF and IR, and complication rate, and in the meta-analysis, the complication rate was lower in the IG group compared with the SCR group. The graft retear rate was slightly lower in the IG group but did not show statistical significance, and results were not affected by graft type in this meta-analysis.

Two recent systematic reviews have evaluated IG and SCR for massive irreparable RCTs. Wall et al reviewed 16 articles published from 2014 to 2017 and documented the surgical techniques and the results of several biomechanical and animal studies. They concluded...
that, as no known literature comparing the 2 procedures existed, it was difficult to definitively assess the outcomes of IG and SCR. More recently, Lin et al reviewed 23 articles published from 2006 to 2019 and concluded that the IG group showed significantly better clinical and functional outcomes postoperatively than the SCR group. We tried to compare the effectiveness of IG and SCR more thoroughly, including more recent studies and using meta-analysis.

In this study, the mean differences in ASES scores of all included studies were 34.42 ± 11.81 and 38.17 ± 11.99 for the IG and the SCR groups, respectively, and they were 43.49 (95% CI, 24.29-62.70) and 36.68 (95% CI, 28.27-45.09) for the IG and the SCR groups, respectively, of the studies included in the meta-analysis. We believe the results of the meta-analysis are more reliable, as it was a more homogeneous comparison of the arthroscopic surgery. We should be cautious when interpreting the results, as there was no significant difference between groups in the meta-analysis, and the differences did not reach the MCID for the ASES (12 points, as reported previously). How-ever, when compared with a systematic review, which evaluated the change in postoperative ASES scores in patients undergoing arthroscopic repair of massive RCTs (mean difference, 32.5%), the improvement in ASES score was comparable or even better in both groups, especially in the IG group.

The overall graft retear rate was not statistically significant between groups. In this study, we included the retear on the repaired infraspinatus as one of the graft retears, because it could affect the healing and function of the IG, and it was the most common retear site in the IG group (19 of 38 retear cases). If we had excluded this repaired infraspinatus from the graft retear cases, the difference may have been significant. However, we should be cautious that various factors, including the diagnostic modality (US or MRI), patient age, sex, and fatty infiltration of the rotator cuff muscles, may affect the results. Specifically, the fatty infiltration of the infraspinatus has been reported as a single independent prognostic factor in the massive RCTs. It is important to consider that the SCR group had significantly worse preoperative status, with the exception of the Constant score (Appendix Table A5), and a significantly higher fatty infiltration grade (Appendix Table A1).

The subgroup analysis of the autografts showed a higher graft retear rate in the IG group. This result may be because there were only 2 studies in the autograft subgroup of the IG group, and 1 of those studies included only grade 3 or 4 fatty infiltration of the infraspinatus and showed an 89.4% graft retear rate. Unlike the graft retear site in the IG group, the most common graft retear site in the SCR group was the lateral humeral attachment site (31 of 46 retear cases). As Lim et al reported, greater stress and abrasion seem to be concentrated on the distal portion
of the SCR graft rather than the medial glenoid site during active shoulder abduction and elevation via acromiohumeral impact, which causes the retears on the lateral humeral side.

The IG group showed significantly lower complication rate (1.12%) compared with the SCR group (8.37%) in the meta-analysis. Moreover, the severe complication of deep wound infection occurred only in 1 case in the IG group, compared with the 3 cases in the SCR group. The 1 deep wound infection in the IG group was related to the patient’s immunocompromised condition, and it resolved after arthroscopic irrigation and debridement. Among the 3 deep infections in the SCR group, 2 were resolved by arthroscopic irrigation and debridement without removing the reconstructed superior capsule, but 1 required additional placement of an antibiotic spacer. In addition, there were no anchor-related complications in the IG group, compared with the 4 anchor pullouts in the SCR group. The reduced tension in the IG group may be the reason for the low number of anchor-related complications. Considering the previously reported complication rate associated with arthroscopic shoulder surgery (5.8%-9.5%), the complication rate of IG seems to be very satisfactory. There are concerns regarding the possibilities of immunologic reaction of the allograft due to DNA from an allogenic source. However, there were no graft rejection cases in either group. Rather, there was a donor site–related complication in the autograft case. Thus, we conclude that allograft is a good option for both IG and SCR as an easy-to-use, strong, and safe scaffold. Regarding graft type, it is hard to recommend which graft is better than the others because we could not compare xenograft and synthetic since these were not used in the SCR group.

The goals of surgery in patients with irreparable RCTs are to reduce pain, restore shoulder function, minimize complications, and delay the development of advanced cuff tear arthropathy. SCR was developed to improve glenohumeral kinematics by preventing humeral head superior migration and recentering the glenohumeral articulation, and it has been shown to improve function. However, SCR is basically a salvage surgery, which gives up the active muscle function of the posterosuperior rotator cuff. On the other hand, IG preserves rotator cuff muscle function and restores balanced shoulder mechanics by reconnecting the viable cuff tendon with less tension to the footprint through a graft. This is an area needed for future study.

There are several limitations in the present study. First, the sample size was relatively small in this systematic review, as we applied strict inclusion and exclusion criteria and as SCR is a recently developed surgical procedure. Second, there may have been some overlap of patients who participated in studies conducted at the same research center, even though we tried to remove duplicate data. More high-quality studies with larger sample sizes are needed to show statistical significance in the meta-analysis and confirm the results. Fourth, the data of the included studies were heterogeneous. Although we presented a comprehensive review of the literature on IG and SCR following PRISMA guidelines and performed the meta-analysis using a random-effects model, which has a conservative nature on forest plots, the heterogeneity of the data made comparisons difficult and potentially problematic. The baseline characteristics for sex, fatty infiltration of each rotator cuff muscle, surgical method and position, and follow-up period were not the same between the IG and SCR groups, which may have acted as a bias. In fact, it is likely that the surgeon’s consideration for each procedure was different: SCR may be more useful in cases with a high Goutallier grade, and IG may be more useful if the quality of the rotator cuff muscles is still preserved. This variability in the included patients should be considered when interpreting the results. Notwithstanding these limitations, we believe that this systematic review and meta-analysis provides valuable information for orthopaedic surgeons planning the use of IG or SCR for irreparable RCTs.

CONCLUSION

Both IG and SCR techniques resulted in improvement in patients with irreparable RCTs. Meta-analysis showed a lower complication rate in the IG group; however, the lack of randomized studies limited our conclusions.

ACKNOWLEDGMENT

The authors thank So Jung Shin for support with data analysis.

REFERENCES

1. Adams CR, DeMartino AM, Rego G, Denard PJ, Burkhart SS. The rotator cuff and the superior capsule: why we need both. Arthroscopy. 2016;32(12):2628-2637.
2. Anderson K, Boothby M, Aschenbrener D, van Holsbeeck M. Outcome and structural integrity after arthroscopic rotator cuff repair using 2 rows of fixation: minimum 2-year follow-up. Am J Sports Med. 2006;34(12):1899-1905.
3. Anley CM, Chan SK, Snow M. Arthroscopic treatment options for irreparable rotator cuff tears of the shoulder. World J Orthop. 2014;5(5):557.
4. Audenaert E, Van Nuffel J, Schepens A, Verhelst M, Verdonk R. Reconstruction of massive rotator cuff lesions with a synthetic interposition graft: a prospective study of 41 patients. Knee Surg Sports Traumatol Arthrosc. 2006;14(4):360-364.
5. Badhe SP, Lawrence TM, Smith F, Lunn P. An assessment of porcine dermal xenograft as an augmentation graft in the treatment of extensive rotator cuff tears. J Shoulder Elbow Surg. 2008;17(1_suppl): S35-S39.

6. Boileau P, Gonzalez J-F, Chuintard C, Bicknell R, Walch G. Reverse total shoulder arthroplasty after failed rotator cuff surgery. J Shoulder Elbow Surg. 2009;18(4):600-606.

7. Bond JL, Dopirak RM, Higgins J, Burns J, Snyder SJ. Arthroscopic replacement of massive, irreparable rotator cuff tears using a Graft-Jacket allograft: technique and preliminary results. Arthroscopy. 2008;24(4):403.

8. Burkhardt SS, Hartzler RU. Superior capsular reconstruction reverses profound pseudoparalysis in patients with irreparable rotator cuff tears and minimal or no glenohumeral arthritis. Arthroscopy. 2019;35(1):22-28.

9. Burkhardt SS, Pranckun JJ, Hartzler RU. Superior capsular reconstruction for the operatively irreparable rotator cuff tear: clinical outcomes are maintained 2 years after surgery. Arthroscopy. 2020;36(2):373-380.

10. Chung SW, Kim JY, Kim MH, Kim SH, Oh JH. Arthroscopic repair of massive rotator cuff tears: outcome and analysis of factors associated with healing failure or poor postoperative function. Am J Sports Med. 2013;41(7):1674-1683.

11. Cofield RH, Briggs B. Glenohumeral arthrodesis. Operative and long-term functional results. J Bone Joint Surg Am. 1979;61(5):688-677.

12. de Campos Azevedo CI, Andrade R, Ángelo ACLPG, et al. Fascia lata autograft versus human dermal allograft in arthroscopic superior capsular reconstruction for irreparable rotator cuff tears: a systematic review of clinical outcomes. Arthroscopy. 2020;36(2):579-591.

13. Denard PJ, Brady PC, Adams CR, Tokish JM, Burkhardt SS. Preliminary results of arthroscopic superior capsule reconstruction with dermal allograft. Arthroscopy. 2018;34(1):93-99.

14. Derwin KA, Baker AR, Spragg RK, Leigh DR, Iannotti JP. Commercial extracellular matrix scaffolds for rotator cuff tendon repair: biomechanical, biochemical, and cellular properties. J Bone Joint Surg Am. 2006;88(12):2665-2672.

15. Elhassan BT, Wagner ER, Werthel J-D. Outcome of lower trapezius transfer to reconstruct massive irreparable posterior-superior rotator cuff tear. J Shoulder Elbow Surg. 2016;25(8):1346-1353.

16. Fenlin JM Jr, Chase JM, Rushton SA, Frieman BG. Tuberoplasty: a review of clinical outcomes. Am J Sports Med. 1988;232:51-61.

17. Gerber C, Vinh TS, Hertel R, Hess CW. Latissimus dorsi transfer for the treatment of massive tears of the rotator cuff. A preliminary report. Clin Orthop Relat Res. 1988;232:51-61.

18. Gouk CJ, Shulman RM, Buchan C, Thomas MJE, Taylor FJ. Failure of dermal allograft repair of massive rotator cuff tears in magnetic resonance imaging and clinical assessment. Clin Orthop Surg. 2019;11(2):200-207.

19. Goutallier D, Postel J-M, Bernageau J, Lavau L, Voisin M-C. Fatty degeneration in the rotator cuff of the shoulder. Clin Orthop Relat Res. 1988;232:54-61.

20. Gupta AK, Hug K, Berkoff DJ, et al. Dermal tissue matrix xenografts: a successful alternative to traditional treatment of massive rotator cuff tears. J Shoulder Elbow Surg. 2013;22(4):769-775.

21. Gupta AK, Hug K, Boggess B, Gavigan M, Toth AP. Massive or large rotator cuff tears in active patients with minimal glenohumeral arthritis: clinical and radiographic outcomes of reconstruction using dermal tissue matrix xenograft. Am J Sports Med. 2013;41(4):872-879.

22. Hirahara AM, Andersen WJ, Panero AAJ. Superior capsular reconstruction: clinical outcomes after minimum 2-year follow-up. Am J Orthop. 2017;46(6):266-272.

23. Holmgren T, Öberg B, Adolfsson L, Hallgren HB, Johansson K. Minimal important changes in the Constant-Murley score in patients with subacromial pain. J Shoulder Elbow Surg. 2014;23(8):1083-1090.

24. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13.

25. Kim DY, Hwang JT, Lee SS, Lee JH, Cho MS. Prevalence of rotator cuff diseases in adults older than 40 years in or near Chuncheon city, Korea. Clin Shoulder Elb. 2020;23(3):125-130.

26. Kim J, Ryu Y, Kim SH. Surgical options for failed rotator cuff repair, except arthroplasty: review of current methods. Clin Shoulder Elb. 2020;23(1):48-58.

27. Klinger H-M, Spahn G, Baums M, Stecket H. Arthroscopic debridement of irreparable massive rotator cuff tears—A comparison of debridement alone and combined procedure with biceps tenotomy. Acta Chir Belg. 2005;105(3):297-301.

28. Lee S-J, Min Y-K. Can inadequate acromiohumeral distance improve and poor posterior remnant tissue be the predictive factors of re-tear? Preliminary outcomes of arthroscopic superior capsular reconstruction. Knee Surg Sports Traumatol Arthros. 2018;26(7):2205-2213.

29. Lim S, AlRamadhan H, Kwak J-M, Hong H, Jeon I-H. Graft tears after arthroscopic superior capsule reconstruction (ASCR): pattern of failure and its correlation with clinical outcome. Arch Orthop Trauma Surg. 2019;139(2):231-239.

30. Lin J, Sun Y, Chen Q, Liu S, Ding Z, Chen J. Outcome comparison of graft bridging and superior capsule reconstruction for large to massive rotator cuff tears: a systematic review. Am J Sports Med. 2020;48(11):2829-2838.

31. Mihata T, Lee TQ, Fukunishi K, et al. Return to sports and physical work after arthroscopic superior capsule reconstruction among patients with irreparable rotator cuff tears. Am J Sports Med. 2018;46(5):1077-1083.

32. Mihata T, Lee TQ, Hasegawa A, et al. Arthroscopic superior capsule reconstruction can eliminate pseudoparalysis in patients with irreparable rotator cuff tears. Am J Sports Med. 2018;46(11):2707-2716.

33. Mihata T, Lee TQ, Watanebe C, et al. Clinical results of arthroscopic superior capsule reconstruction for irreparable rotator cuff tears. Arthroscopy. 2013;29(3):459-470.

34. Mihata T, McGarry MH, Pirolo JM, Kinoshita M, Lee TQ. Superior capsule reconstruction to restore superior stability in irreparable rotator cuff tears: a biomechanical cadaveric study. Am J Sports Med. 2012;40(10):2248-2255.

35. Modi A, Singh HP, Pandey R, Armstrong A. Management of irreparable rotator cuff tears with the GraftJacket allograft as an interpositional graft. Shoulder Elbow. 2013;5(3):188-194.

36. Moher D, Liberati A, Tetzlaff J, Altman DG the PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.

37. Mori D, Funakoshi N, Yamashita F. Arthroscopic surgery of irreparable large or massive rotator cuff tears with low-grade fatty degeneration of the infraspinatus: patch autograft procedure versus partial repair procedure. Arthroscopy. 2013;29(12):1911-1921.

38. Mori D, Funakoshi N, Yamashita F, Wakabayashi T. Effect of fatty degeneration of the infraspinatus on the efficacy of arthroscopic patch autograft procedure for large to massive rotator cuff tears. Am J Sports Med. 2015;43(5):1108-1117.

39. Mulieri P, Dunning P, Klein S, Pupello D, Frankie M. Reverse shoulder arthroplasty for the treatment of irreparable rotator cuff tear without glenohumeral arthritis. J Bone Joint Surg Am. 2010;92(15):2544-2556.

40. Neumann JA, Zgonis MH, Rickert KD, et al. Interposition dermal matrix xenografts: a successful alternative to traditional treatment of massive rotator cuff tears. Am J Sports Med. 2017;45(6):1261-1268.

41. Nevisier JS, Nevisier RJ, Nevisier TJ. The repair of chronic massive ruptures of the rotator cuff of the shoulder by use of a freeze-dried rotator cuff. J Bone Joint Surg Am. 1978;60(5):681-684.

42. Obremskey WT, Pappas N, Atallah-Wasif E, Tornetta P III, Bhandari M. Level of evidence in orthopaedic journals. J Bone Joint Surg Am. 2005;87(12):2632-2638.
APPENDIX

APPENDIX TABLE A1
Comparison of the Baseline Characteristics Between the IG and SCR Groupsa

| Characteristic                      | IG Group | SCR Group | P   |
|------------------------------------|----------|-----------|-----|
| Age, y, mean ± SD                  | 61.96 ± 5.19 | 63.1 ± 2.93 | .044 |
| Sex, male:female, n                | 183:174 | 168:95 | .002 |
| Dominant arm affected, n/N (%)     | 64/94 (68.1) | 60/80 (75) | .315 |
| Follow-up period, mo, mean ± SD    | 35.92 ± 9.55 | 19.25 ± 7.71 | <.001 |
| Fatty infiltration grade, mean ± SDb | 2.97 ± 0.62 | 2.79 ± 0.07 | .091 |
| SST                                | 2.02 ± 0.16 | 2.68 ± 0.13 | <.001 |
| IST                                | 0.50 ± 0   | 1.33 ± 0.17 | <.001 |

aBolded P values indicate statistically significant difference between groups (P < .05). IG, interposition grafting; IST, infraspinatus; SCR, superior capsular reconstruction; SSC, subscapularis; SST, supraspinatus.
bAccording to Goutallier et al.19
## APPENDIX TABLE A2

**MINORS Scores of Included Studies**

| Lead Author (Year) | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | Total Score | Ideal Score |
|--------------------|---|---|---|---|---|---|---|---|---|----|----|----|----|------------|-------------|
| Audenaert (2006)   | 2 | 2 | 2 | 0 | 0 | 2 | 2 | 0 | N/A| N/A| N/A| N/A| N/A| 10          | 16          |
| Badhe (2008)       | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | N/A| N/A| N/A| N/A| N/A| 13          | 16          |
| Wong (2010)        | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | N/A| N/A| N/A| N/A| N/A| 13          | 16          |
| Gupta (2012)       | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | N/A| N/A| N/A| N/A| N/A| 13          | 16          |
| Gupta (2013)       | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | N/A| N/A| N/A| N/A| N/A| 13          | 16          |
| Mori (2013)        | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 2  | 2  | 2  | 2  | N/A| 20          | 24          |
| Mori (2015)        | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 1 | 0  | 2  | 2  | 2  | N/A| 20          | 24          |
| Neumann (2017)     | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 1 | 0  | N/A| N/A| N/A| N/A| N/A| 12          | 16          |
| Pandey (2017)      | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 2  | 1  | 0  | 2  | N/A| 19          | 24          |
| Seker (2018)       | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 0  | N/A| N/A| N/A| N/A| N/A| 13          | 16          |
| Hirahara (2017)    | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 0  | N/A| N/A| N/A| N/A| N/A| 11          | 16          |
| Pennington (2018)  | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 0  | N/A| N/A| N/A| N/A| N/A| 16          | 16          |
| Mihata (2018)      | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | N/A| N/A| N/A| N/A| N/A| 12          | 16          |
| Lee (2018)         | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 2 | N/A| N/A| N/A| N/A| N/A| 14          | 16          |
| Denard (2018)      | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | N/A| N/A| N/A| N/A| N/A| 11          | 16          |
| Lim (2019)         | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | N/A| N/A| N/A| N/A| N/A| 14          | 16          |
| Burkhart (2020)    | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | N/A| N/A| N/A| N/A| N/A| 14          | 16          |

*aEach item is scored 0 (not reported), 1 (reported but inadequate) or 2 (reported and adequate). MINORS, methodological index for non-randomized studies; N/A, not accessed.

**Key to items:**
1. A clearly stated aim: the question addressed should be precise and relevant in the light of available literature.
2. Inclusion of consecutive patients: all patients potentially fit for inclusion (satisfying the criteria for inclusion) have been included in the study during the study period (no exclusion or details about the reasons for exclusion).
3. Prospective collection of data: data were collected according to a protocol established before the beginning of the study.
4. Endpoints appropriate to aim of study: unambiguous explanation of the criteria used to evaluate the main outcome which should be in accordance with the question addressed by the study. Also, the endpoints should be assessed on an intention-to-treat basis.
5. Unbiased assessment of study endpoint: blind evaluation of objective endpoints and double-blind evaluation of subjective endpoints. Otherwise, the reasons for not blinding should be stated.
6. Follow-up period appropriate to aim of study: the follow-up should be sufficiently long to allow the assessment of the main endpoint and possible adverse events.
7. Loss of follow-up less than 5%: all patients should be included in the follow-up. Otherwise, the proportion lost to follow-up should not exceed the proportion experiencing the major endpoint.
8. Prospective calculation of study size: information of the size of detectable difference of interest with a calculation of 95% CI, according to the expected incidence of the outcome event, and information about the level for statistical significance and estimates of power when comparing the outcomes.
9. Additional criteria in the case of comparative study.
10. An adequate control group: having a gold standard diagnostic test or therapeutic intervention recognized as the optimal intervention according to the available published data.
11. Contemporary groups: control and studied group should be managed during the same time period (no historical comparison).
12. Baseline equivalence of groups: the groups should be similar regarding the criteria other than the studied endpoints.
13. Adequate statistical analyses: whether the statistics were in accordance with the type of study with calculation of CIs or relative risk.

## APPENDIX TABLE A3

**Summary of Outcomes Except for Range of Motion**

| Lead Author (Year) | Pain VAS | ASES | Constant | Complete Graft Retear Rate (%) | Imaging Method | Complication Rate (%) |
|--------------------|----------|------|----------|-------------------------------|----------------|------------------------|
|                    | Preop | Postop | Preop | Postop | Preop | Postop | Preop | Postop | | | |
| Audenaert (2006)   | NR    | NR    | NR    | NR    | 25.7 | 72.1 | 2.44 | US | 0 | |
| Badhe (2008)       | NR    | NR    | NR    | NR    | 41.5 | 62.2 | 20 | US/MRI | 0 | |
| Wong (2010)        | NR    | NR    | NR    | 84.1  | NR   | NR   | 0 | MRI | 2.22 | |
| Gupta (2012)       | 5.4   | 0.9   | 66.6  | 88.7  | NR   | NR   | 0 | US | 0 | |
| Gupta (2013)       | 5.1   | 0.4   | 62.7  | N/A   | NR   | NR   | 4.55 | US | 0 | |
| Mori (2013)        | 7.0±0.9 | 0.3±0.6 | 40.8±13.0 | 94.1±5.4 | 37.4±8.1 | 81.1±5.7 | 20.83 | MRI | 0 | |
| Mori (2015)        | NR    | NR    | 39.9±9.9 | 73.6±10.1 | 40.7±0.7 | 69.3±6.0 | 89.40 | MRI | 0 | |
| Neumann (2017)     | 4     | 1     | NR    | 87.8  | NR   | NR   | 4.90 | US | 0 | |
| Pandey (2017)      | NR    | NR    | NR    | NR    | 41.2±3.1 | 83.9±6.0 | 30 | US | 0 | |

(continued)
Appendix Table A3 (continued)

| Lead Author (Year) | Pain VAS | ASES | Constant | Complete Graft Retear Rate (%) | Imaging Method | Complication Rate (%) |
|--------------------|----------|------|----------|-------------------------------|----------------|-----------------------|
| Seker (2018)       | NR       | NR   | 95 ± 7.67| NR 90 ± 11.63                 | US             | 5                     |

Superior Capsular Reconstruction

| Lead Author (Year) | Pain VAS | ASES | Constant | Complete Graft Retear Rate (%) | Imaging Method | Complication Rate (%) |
|--------------------|----------|------|----------|-------------------------------|----------------|-----------------------|
| Hirahara (2017)    | 6.25 ± 1.56 | 0.38 ± 1.06 | 41.75 ± 12.71 | 86.5 ± 12.66 | NR | NR | 25 | US/MRI | 0 |
| Pennington (2018)  | 4.03 ± 2.55 | 1.51 ± 1.21 | 52.22 ± 19.29 | 81.56 ± 10.21 | NR | NR | 3.49 | MRI | NR |
| Mihata (2018)      | NR | NR | 36 ± 19 | 92 ± 12 | NR | NR | 5 | MRI | 16 |
| Lee (2018)         | 5.8 ± 1.2 | 1.0 ± 0.8 | 52.1 ± 9.3 | 85.4 ± 4.2 | 56.10 ± 9.00 | 83.5 ± 5.0 | 36.11 | US/MRI | NR |
| Denard (2018)      | 5.8 ± 2.2 | 1.7 ± 2.1 | 43.6 ± 18.6 | 77.5 ± 22.0 | NR | NR | 18.64 | MRI | 6.8 |
| Lim (2019)         | 6 ± 1.2 | 2.5 ± 1.2 | 54.4 ± 17.9 | 73.7 ± 10.8 | 51.7 ± 13.9 | 63.7 ± 8.1 | 29.03 | MRI | 0 |
| Burkhart (2020)    | 4.6 | 0.7 | 52 ± 3 | 89 ± 2 | NR | NR | 11 | MRI | 0 |

aASES, American Shoulder and Elbow Surgeons score; MRI, magnetic resonance imaging; NR, not reported; Postop, postoperative; Preop, preoperative; US, ultrasound; VAS, visual analog scale.

APPENDIX TABLE A4
Summary of Range-of-Motion Outcomes

| Lead Author (Year) | Active FF, deg | Active ABD, deg | Active ER, deg | Active IR<sup>d</sup> | Preop | Postop | Preop | Postop | Preop | Postop | Preop | Postop |
|--------------------|---------------|-----------------|----------------|----------------------|-------|--------|-------|--------|-------|--------|-------|--------|
|                     |               |                 |                |                      |       |        |       |        |       |        |       |        |
| Audenaert (2006)<sup>4</sup> | 69.2       | 136             | 68.4           | 133.7                | 32.4  | 38.3   | 3.4<sup>e</sup> | 7.5<sup>f</sup> |
| Badhe (2008)<sup>5</sup>     | NR           | NR              | NR             | NR                   | NR    | NR     | NR    | NR     | NR    | NR     |
| Wong (2010)<sup>58</sup>    | NR           | NR              | NR             | NR                   | NR    | NR     | NR    | NR     | NR    | NR     |
| Gupta (2012)<sup>59</sup>   | 111.7        | 157.3           | 105            | 151.7                | 46.2  | 65.1   | NR    | NR     | NR    | NR     |
| Gupta (2013)<sup>53</sup>   | 138.8        | 167.3 ± 12.1    | 117.9          | 149.3                | 57.7  | 64.7 ± 16.8 | NR    | NR     | NR    | NR     |
| Mori (2013)<sup>57</sup>    | 114.0 ± 31.4 | 160.8 ± 9.6     | NR             | NR                   | 27.9 ± 16.4 | 46.0 ± 14.7 | 17.0 ± 2.6 | 11.6 ± 2.5 |
| Mori (2015)<sup>58</sup>    | 110.6 ± 34.2 | 162.3 ± 9.4     | NR             | NR                   | 33.7 ± 24.4 | 37.1 ± 25.2 | 14.2 ± 2.2 | 12.8 ± 2.0 |
| Neumann (2017)<sup>50</sup>| 140.7        | 160.4           | NR             | NR                   | 55.6  | 70.1   | 52<sup>d</sup> | 76.2<sup>d</sup> |
| Pandey (2017)<sup>43</sup>| NR           | NR              | NR             | NR                   | NR    | NR     | NR    | NR     | NR    | NR     |
| Seker (2018)<sup>47</sup>  | 120          | 162             | 105            | 151                  | 32    | 50     | 17    | 11     |       |        |

(continued)
### APPENDIX TABLE A5
Comparison Between Groups in Clinical Outcomes

| IG | SCR | \( P \) |
|----|-----|----------|
| Pain VAS (n = 136) | (n = 263) | \(<.001\) |
| Preop | 4.99 ± 1.09 | 5.06 ± 0.86 |
| Postop | 0.74 ± 0.30 | 1.45 ± 0.54 |
| Mean difference | 4.26 ± 1.35 | 3.61 ± 0.89 |
| ASES (n = 94) (n = 363) | \(<.001\) |
| Preop | 53.50 ± 12.18 | 46.27 ± 7.22 |
| Postop | 87.92 ± 7.50 | 84.43 ± 6.17 |
| Mean difference | 34.42 ± 11.81 | 38.17 ± 11.99 |
| Constant (n = 107) (n = 67) | \(<.001\) |
| Preop | 34.35 ± 6.99 | 54.24 ± 2.40 |
| Postop | 73.17 ± 7.45 | 73.98 ± 9.64 |
| Mean difference | 38.82 ± 10.21 | 19.74 ± 7.32 |
| Active FF, deg (n = 254) (n = 355) | \(<.001\) |
| Preop | 116.72 ± 23.77 | 115.75 ± 17.83 |
| Postop | 157.45 ± 9.73 | 154.52 ± 7.90 |
| Mean difference | 40.73 ± 15.74 | 38.77 ± 13.78 |
| Active ER, deg (n = 254) (n = 287) | \(<.001\) |
| Preop | 41.55 ± 11.59 | 32.13 ± 5.77 |
| Postop | 54.59 ± 12.54 | 45.41 ± 9.00 |
| Mean difference | 13.04 ± 5.57 | 13.28 ± 5.85 |
| Active IR \(b\) (n = 101) (n = 195) | \(<.001\) |
| Preop | 16.47 ± 1.10 | 15.20 ± 1.01 |
| Postop | 11.48 ± 0.68 | 12.82 ± 0.39 |
| Mean difference | 4.99 ± 1.76 | 2.38 ± 0.68 |

Values are presented as mean ± SD. Bolded \( P \) values indicate statistically significant difference between groups (\( P < .05 \)). IG, interposition grafting; SCR, superior capsular reconstruction.

### APPENDIX TABLE A6
Comparison Between Groups in Graft Retear Rate and Complication Rate

| IG | SCR | \( P \) |
|----|-----|----------|
| Graft retear rate, % (n) | \(<.001\) |
| Total | 10.6 (38 of 357) | 12.7 (46 of 363) |
| Autograft | 51.2 (22 of 43) | 10.7 (14 of 131) |
| Allograft | 3.4 (4 of 117) | 8.7 (17 of 196) |
| Complication rate, % (n) | \(<.001\) |
| Total | 1.1 (4 of 357) | 8.4 (20 of 239) |
| Autograft | 0 (0 of 43) | 12.2 (16 of 131) |
| Allograft | 0.9 (1 of 117) | 3.7 (4 of 108) |

Bolded \( P \) values indicate statistically significant difference between groups (\( P < .05 \)). IG, interposition grafting; SCR, superior capsular reconstruction.

---

\(a\)Values are presented as mean ± SD. Bolded \( P \) values indicate statistically significant difference between groups (\( P < .05 \)). ASES, American Shoulder and Elbow Surgeons score; ER, external rotation at the side; FF, forward flexion; IR, internal rotation; NR, not reported; Postop, postoperative; Preop, preoperative.

\(b\)Unless otherwise indicated, internal rotation was estimated by determining how far the patient’s thumb could reach along the spinal segments. For the statistical analysis, the spinal segment was converted into numbers: segments from T1 to T12 were designated as 1-12, segments from L1 to L5 were designated as 13-17, and the sacrum was designated as 18.

\(c\)Internal rotation was estimated by the Constant and Murley score.

\(d\)Internal rotation was estimated at 90° of abduction.
**APPENDIX TABLE A7**

|     | SCR | IG |
|-----|-----|----|
|     | Autograft\(^a\), Allograft\(^{9,13,22,44}\), Autograft + Allograft\(^{28}\) | Autograft\(^{37,38}\), Allograft\(^{20,43,58}\), Xenograft\(^{5,21,40}\), Synthetic\(^{4,47}\) |
| Pain VAS | 3.50, 3.29, 4.73 | 6.70, 4.50, 3.52, NR |
| Constant | 12.00, NR, 26.40 | 34.64, 42.70, 20.70, 46.40 |
| ASES | 47.31, 32.94, 33.66 | 44.63, 22.10, 29.10, NR |
| Active FF | 45.82, 32.93, 43.63 | 48.96, 45.60, 22.40, 52.27 |
| Active ER | 11.92, 14.33, 15.32 | 11.60, 18.90, 12.19, 12.98 |
| Active IR\(^b\) | 3.00, 2.00, 5.26 | 3.63, NR, NR, 6.00 |
| Active ABD | NR, 56.00, NR | NR, 46.70, 31.40, 53.99 |
| SST strength | NR, 22.24, NR | NR, 45.00, NR, NR |
| Graft retear | 5.94, 5.36, 5.91 | 10.30, 0.44, 2.34, 3.34 |
| Complications | 12.21, 2.18, NR | 0, 0.68, 0, 1.75 |

\(^a\)ABD, abduction; ASES, American Shoulder and Elbow Surgeons score; ER, external rotation at the side; FF, forward flexion; IG, interposition grafting; IR, internal rotation; NR, not reported; SCR, superior capsular reconstruction; SST, supraspinatus; VAS, visual analog scale.

\(^b\)Active IR was compared in the studies that assessed the IR by using the vertebral level (levels T1-T12 were designated as 1-12, levels L1-L5 were designated as 13-17, and the sacrum was designated as 18).\(^{28}\)

---

**Appendix Figure A1.** Forest plot comparing the American Shoulder and Elbow Surgeons score between the interposition grafting (IG) and superior capsular reconstruction (SCR) groups.
Appendix Figure A2. Forest plot comparing the graft retear rate between the interposition grafting (IG) and superior capsular reconstruction (SCR) groups.

Appendix Figure A3. Forest plot comparing the graft retear rate of the autograft between the interposition grafting (IG) and superior capsular reconstruction (SCR) groups.
Appendix Figure A4. Forest plot comparing the graft retear rate of the allograft between the interposition grafting (IG) and superior capsular reconstruction (SCR) groups.

Appendix Figure A5. Forest plot comparing the complication rate of the autograft between the interposition grafting (IG) and superior capsular reconstruction (SCR) groups.
### Group by subgroup

| Study Name               | Event Rate | Lower Limit | Upper Limit | Z Value | P Value | Total |
|--------------------------|------------|-------------|-------------|---------|---------|-------|
| IG                       | 0.013      | 0.002       | 0.083       | -4.342  | 0.000   | 1/80  |
| Gupta et al (2012)       | 0.020      | 0.001       | 0.251       | -2.724  | 0.006   | 0/24  |
| Pandey et al (2017)      | 0.036      | 0.002       | 0.384       | -2.299  | 0.022   | 0/13  |
| Subtotal                 | 0.018      | 0.005       | 0.070       | -5.580  | 0.000   |       |
| SCR                      | 0.056      | 0.003       | 0.505       | -1.947  | 0.052   | 0/8   |
| Denard et al (2018)      | 0.008      | 0.001       | 0.120       | -3.365  | 0.001   | 0/59  |
| Burkhart et al (2020)    | 0.098      | 0.037       | 0.233       | -4.227  | 0.000   | 0/41  |
| Subtotal                 | 0.055      | 0.014       | 0.160       | -4.007  | 0.000   |       |
| Overall                  | 0.032      | 0.012       | 0.081       | -6.775  | 0.000   |       |

**Event rate and 95% CI**

| Relative weight |
|-----------------|
| 50.39           |
| 25.00           |
| 24.00           |
| 18.92           |
| 19.66           |
| 61.42           |

Heterogeneity: Tau² = 0.00 (IG), 0.54 (SCR); Chi² = 0.37 (IG), 2.88 (SCR); df = 2 (IG, p = .827), 2 (SCR, p = .237); F = 0.00 (IG), 30.62 (SCR)

Test for overall effect: Z = 1.67 (p = .0958)

---

**Appendix Figure A6.** Forest plot comparing the complication rate of the allograft between the interposition grafting (IG) and superior capsular reconstruction (SCR) groups